Your browser doesn't support javascript.
loading
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
Tarantino, P; Burstein, H J; Lin, N U; Krop, I E; Winer, E P; Schnitt, S J; Hamilton, E P; Hurvitz, S A; Rugo, H S; Curigliano, G; Tolaney, S M.
Affiliation
  • Tarantino P; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA.
  • Burstein HJ; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA.
  • Lin NU; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA.
  • Krop IE; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA.
  • Winer EP; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA.
  • Schnitt SJ; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA; Department of Pathology, Brigham and Women's Hospital, Boston, USA.
  • Hamilton EP; Breast and Gynecologic Cancer Research, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA.
  • Hurvitz SA; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, USA.
  • Rugo HS; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
  • Curigliano G; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Tolaney SM; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: Sara_Tolaney@dfci.harvard.edu.
Ann Oncol ; 33(3): 234-238, 2022 03.
Article in En | MEDLINE | ID: mdl-34942341
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans Language: En Journal: Ann Oncol Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans Language: En Journal: Ann Oncol Year: 2022 Document type: Article